48,335 Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Purchased by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. acquired a new stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 48,335 shares of the company’s stock, valued at approximately $259,000. Balyasny Asset Management L.P. owned approximately 0.08% of Corvus Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in Corvus Pharmaceuticals by 441.5% during the third quarter. JPMorgan Chase & Co. now owns 49,556 shares of the company’s stock valued at $262,000 after buying an additional 40,404 shares in the last quarter. Barclays PLC raised its stake in Corvus Pharmaceuticals by 10,601,800.0% during the fourth quarter. Barclays PLC now owns 106,019 shares of the company’s stock valued at $567,000 after buying an additional 106,018 shares in the last quarter. PKS Advisory Services LLC acquired a new stake in Corvus Pharmaceuticals during the fourth quarter valued at approximately $56,000. Nwam LLC raised its stake in Corvus Pharmaceuticals by 54.2% during the fourth quarter. Nwam LLC now owns 15,500 shares of the company’s stock valued at $83,000 after buying an additional 5,450 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Corvus Pharmaceuticals during the fourth quarter valued at approximately $583,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. Oppenheimer reaffirmed an “outperform” rating and set a $17.00 target price (up from $15.00) on shares of Corvus Pharmaceuticals in a report on Friday, May 9th. Finally, StockNews.com raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 12th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $16.33.

Corvus Pharmaceuticals Trading Up 0.8%

NASDAQ:CRVS opened at $3.61 on Friday. The firm has a market capitalization of $246.09 million, a PE ratio of -3.88 and a beta of 0.67. The stock has a 50 day moving average of $3.56 and a 200-day moving average of $5.31. Corvus Pharmaceuticals, Inc. has a 52 week low of $1.75 and a 52 week high of $10.00.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). As a group, analysts predict that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current fiscal year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.